A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo
No takes yet. Share an insight, caveat, or question.
Doan et al. (2024) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: